With a market cap of $149.2 billion, Pfizer Inc. (PFE) is a global biopharmaceutical company that discovers, develops, ...

(NYSE: PFE) today announced detailed progression-free and overall survival results from Cohort 3, a randomized cohort of the Phase 3 BREAKWATER trial, evaluating BRAFTOVI ® (encorafenib) in ...

Pfizer is an over-100-year-old drug company going through a rough patch, which has happened before.

Pfizer-BioNTech said Thursday that it is beginning clinical trials of its COVID-19 vaccine in pregnant women, the first such trials to include expectant mothers in the U.S. The drugmaker aims to ...

Pfizer Inc. and China’s Innovent Biologics Inc. signed a global agreement worth as much as $10.5 billion to develop cancer ...

Pfizer is paying Innovent $650 million upfront to partner on cancer drug development, following Bristol Myers Squibb by ...

The payout ratio is over 100% for this high-yield healthcare giant, but don't run for the hills just yet.

Innovent Biologics rose as much as 10%, after entering a strategic global licensing and collaboration agreement with Pfizer ...

Pfizer reaffirmed its 2026 outlook, expecting full-year adjusted profit to come in between $2.80 and $3 per share, and ...

These healthcare giants have been top dividend stocks for years, and both could be intriguing options to consider right now.

China's Innovent Biologics and U.S. pharma giant Pfizer have agreed to a global licensing and collaboration deal worth up to ...

Pfizer and Innovent Biologics signed a licensing agreement to research and develop 12 cancer medicines. The agreement includes licensing, co-development and co-commercialization across the ...